Neuphoria Therapeutics Inc Ordinary Shares NEUP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.30
- Day Range
- $3.34–3.43
- 52-Week Range
- $3.30–21.38
- Bid/Ask
- $2.51 / $4.48
- Shares Outstanding
- 5.40M
- Market Cap
- $18.05M
- Volume/Avg
- 30 / 65,048
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 8
- Website
- https://www.neuphoriatx.com
Valuation
|
Metric
|
NEUP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NEUP
Financial Strength
|
Metric
|
NEUP
|
|---|---|
Quick Ratio | 13.91 |
Current Ratio | 14.31 |
Interest Coverage | — |
Quick Ratio
NEUP
Profitability
|
Metric
|
NEUP
|
|---|---|
Return on Assets (Normalized) | −43.14% |
Return on Equity (Normalized) | −58.46% |
Return on Invested Capital (Normalized) | −60.64% |
Return on Assets
NEUP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|L#Gqv$b | LOCK|y%RM | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>&LW$c$ | LOCK|$$ZPq | $71B | |||
| argenx SE ADR
ARGX
| LOCK|#CVw@Z | LOCK|tq^ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Gn><my# | LOCK|#np | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|wMP%@v& | LOCK|TMDw | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^b<qyk>^ | LOCK|lB>> | $26B | |||
| Moderna Inc
MRNA
| LOCK|!b>?Pf | LOCK|#<? | $24B | |||
| Incyte Corp
INCY
| LOCK|r@?j@P | LOCK|>^ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|FknJ?T | LOCK|!X | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|Tz@YjH | LOCK|@< | $16B |
United States